LEXINGTON, Mass.--(BUSINESS WIRE)--RainDance Technologies, Inc., the leading provider of microdroplet-based solutions for single molecule and single cell analysis, today announced the publication of two significant studies that further validate the use of the company’s MethylSeq™ Solution to power large-scale epigenetic research projects. Published separately in Genome Research and PLoS ONE, these two studies from scientists at The Scripps Research Institute and Christian-Albrechts University detail how the company’s MethylSeq Solution allows researchers to more accurately target genomic regions of methylation and overcome the many hurdles and costs associated with traditional techniques, such as ChIP-seq and whole-genome bisulfite sequencing.
